BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-05-03 EDT | ||
| 44.93 EUR | -5.36% |
|
| Current month | -8.70% | ||
| 1 month | -7.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 44.76 | -5.73% | 99 |
| 24-05-02 | 47.47 | -3.15% | 92 |
| 24-04-30 | 49.02 | +9.55% | 92 |
| 24-04-29 | 44.74 | -0.81% | 85 |
| 24-04-26 | 45.11 | +2.11% | 83 |
Real-time Euronext Paris
Last update May 03, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| QD98S | |
| ISIN | DE000SF15KF2 |
| Date issued | 2021-07-01 |
| Strike | 256 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.54 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.76 € |
|---|---|
| Lowest since issue | 0.66 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
735
USD
Average target price
848.3
USD
Spread / Average Target
+15.43%
- Stock Market
- Certificates
- QD98S Certificat
